Working… Menu

High Intensity Focused Ultrasound Tumor Treatment for Pancreatic Cancer Pain (HIFU Pancreas)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00637364
Recruitment Status : Suspended (Sponsor is not proceeding with USA human trial at this time)
First Posted : March 18, 2008
Last Update Posted : January 13, 2009
Information provided by:
CMED HIFU Development Corporation

Brief Summary:

This is an open-label, non-randomized, single-center, therapeutic trial in patients with AJCC Stage III or IV pancreatic cancer with tumor related abdominal and/or back pain to evaluate the safety of high intensity focused ultrasound therapy using the FEP-BY02 HIFU system for palliation of pancreatic cancer-related pain. Patients meeting all eligibility criteria without any exclusion criteria will be offered an opportunity to participate in the study. After obtaining informed consent a baseline history, physical examination, laboratory studies, and any additional imaging studies needed will be performed.

The major theoretic risk to the patient with this procedure is the development of acute pancreatitis. If acute pancreatitis were to develop, it should become clinically evident by day 3 following HIFU ablation. Therefore, the initial phase of this pilot study is designed to allow a sufficient interval between HIFU treatments to identify whether this theoretic risk will manifest clinically. Previous clinical experience in China suggests that HIFU of pancreatic tumors is safe without risk of developing severe acute pancreatitis.

Patients treated with HIFU will have approximately 15-20% of the tumor volume treated per session. The first 5 patients (feasibility study) will receive their first HIFU treatment followed by a 3-5 day interval for observation.

Following the feasibility study the results will be reviewed with the FDA. If no serious adverse events are encountered, and the FDA agrees with continuing the study, then the next 5 patients will be treated with an interval of 2-3 days between each treatment. If no serious adverse events are encountered in this group, then the next group of 5 patients will be treated at intervals of 1-2 days between each treatment.

Condition or disease Intervention/treatment Phase
Pain Pancreatic Adenocarcinoma Ductal Adenocarcinoma Procedure: High intensity focused ultrasound, HIFU Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 5 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label, Non-Randomized, Single-Center, Therapeutic Trial Examining the Feasibility, Safety, and Efficacy of FEP-BY02, a High Intensity Focused Ultrasound Tumor Treatment Device, in Patients With Pancreatic Cancer Pain
Study Start Date : March 2008
Estimated Primary Completion Date : July 2010

Resource links provided by the National Library of Medicine

Intervention Details:
  • Procedure: High intensity focused ultrasound, HIFU

    The FEP-BY02 HIFU system uses extracorporeal generated high intensity ultrasound, focused on a tumor region of interest, to ablate tissue. A stand-alone B-mode ultrasound is used to locate and define the tumor region of interest. Once defined, the acoustic energy is delivered using a large aperture; fixed focus; sparse transducer array. The concentration of acoustic energy may result in thermal and/or mechanical bioeffects including tissue necrosis, apoptosis, and/or disruption (temporary or permanent) of normal cellular function within the targeted volume (such as nerve conduction).

    The FEP-BY02 High Intensity Focused Ultrasound (HIFU) system is intended to ablate ductal adenocarcinoma of the pancreas with ultrasound-guided targeted delivery of focused ultrasound energy to effect thermal and/or mechanical bioeffects leading to ablation (destruction) of the targeted tumor tissue.

Primary Outcome Measures :
  1. Safety of the FEP-BY02 HIFU system determined by the frequency and severity of adverse events (AEs) categorized and graded for severity according to the Common Terminology Criteria for Adverse Events, Version 3.0 (CTCAE) [ Time Frame: pre treatment, post treatment, 1 week, 2 weeks, 1 month, 2 months, 3 months, 6 months, 12 months, 18 months, 24 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age older than 18 years
  • Histology proven pancreatic ductal adenocarcinoma in the body or tail of the pancreas with a 1 cm margin of tissue to all named vessels and adjacent organs
  • AJCC stage III or IV pancreatic cancer based on imaging criteria (endoscopic ultrasound, CT scan, and/or MRI)
  • Presence of mid-abdominal pain or back pain (>=4 at its worst on Brief Pain Inventory) in the week prior to baseline evaluation or requiring any dose of opioid narcotic for pain relief
  • Pancreatic tumor that can be evaluated by RECIST criteria
  • Pancreatic tumor that can be imaged with transabdominal ultrasonography
  • Pancreatic tumors with an adequate window for the HIFU beam without intervening air or colon
  • No contraindications for CT/PET imaging
  • Karnofsky's performance status of 50% or greater
  • Life expectancy greater than 3 months
  • Normal coagulation profile (INR <1.6; platelet count >50,000)
  • American Society of Anesthesiologists (ASA) class =/<2, not including patient's diagnosis of pancreatic carcinoma
  • Normal serum uric acid, calcium, potassium, phosphate and creatinine values
  • Willingness and ability to complete follow-up interviews for 24 months following the last HIFU treatment

Exclusion Criteria:

  • Previous pancreatic surgery or resection
  • Have had previous surgery to remove jaundice causing obstruction
  • Active malignancy (not including metastases) or history of other primary source of cancer other than pancreas except for basal cell carcinoma or carcinoma-in-situ of the cervix
  • Any other disease, condition or surgery which might confound HIFU therapy, including the requirement for the patient to remain still in the supine position for 90 minutes
  • Inability to image the pancreatic tumor with ultrasound
  • The presence of bone (e.g., ribs) in the path of the HIFU beam
  • The presence of colon in the path of the HIFU beam
  • Use of aspirin containing or aspirin-analog products, including herbal supplements that may decrease coagulation, within two weeks of first HIFU treatment
  • Currently a prisoner
  • Currently experiencing an episode of major mental illness (psychosis, major affective disorder, or schizophrenia)
  • Pregnancy at time of enrollment, since this would contraindicate HIFU therapy
  • Participation in any other investigational drug, biologic or medical device study within the 30 days prior to the study enrollment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00637364

Layout table for location information
United States, Washington
University of Washington
Seattle, Washington, United States, 98195
Sponsors and Collaborators
CMED HIFU Development Corporation
Layout table for investigator information
Principal Investigator: Joo Ha Hwang, MD, PhD University of Washington

Layout table for additonal information
Responsible Party: Joo Ha Hwang, MD, PhD, University of Washington Identifier: NCT00637364     History of Changes
Other Study ID Numbers: FEP-BY02-01
WIRB 20071832
First Posted: March 18, 2008    Key Record Dates
Last Update Posted: January 13, 2009
Last Verified: January 2009
Keywords provided by CMED HIFU Development Corporation:
pancreatic cancer
pancreatic adenocarcinoma
ductal adenocarcinoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Pancreatic Neoplasms
Cancer Pain
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Neurologic Manifestations
Signs and Symptoms